Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Emraclidine in Healthy Elderly and Alzheimer's Dementia
NCT05644977Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Dec 2022
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of emraclidine in Alzheimer's disease (AD) (6 cohorts), sponsored by AbbVie Inc. Primary endpoints: Treatment-emergent Adverse Events, Clinically Significant Changes in Electrocardiogram Parameters and 7 more. Started Dec 2022; status: completed.
02
Drugs
emraclidine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05644977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05644977.